December 2024 Question CHEST SEEK ® Challenge: Which of the following therapies is contraindicated in the management of this patient’s pulmonary hypertension? The SEEK Challenge question is updated monthly. Check back in January for next month’s question.
Key Updates for Week 50, ending December 14, 2024
This interactive feature describes a 44-year-old woman with a 2-year history of shortness of breath with minimal exertion, cough, fatigue, and unintentional weight loss. Test…
The antiviral effect of Paxlovid (nirmatrelvir/ritonavir) is significantly superior to azvudine among inpatients with COVID-19 pneumonia.
Recognition of autism and autism diagnoses have increased substantially in recent years. But most nonautistic physicians don’t have the skills to effectively engage with autistic…
In sarcoidosis, elevated inflammatory proteins in plasma are evident years before the onset of disease.
Background Uncertainty exists about the beneficial effects of delivering pulmonary rehabilitation (PR) during exacerbations of chronic obstructive pulmonary disease (ECOPD). This study explored the short-term…
Objective Community-acquired pneumonia (CAP) is a leading cause of hospitalisation in older adults and is associated with a high likelihood of adverse outcomes. Given the…
Rationale: Low arousal threshold and poor muscle responsiveness are common determinants of obstructive sleep apnea (OSA). Hypnotics were hypothesized as an alternative OSA treatment via…
Elexacaftor/tezacaftor/ivacaftor (ETI) has had a substantial positive impact for people living with cystic fibrosis (pwCF). However, there can be substantial variability in efficacy, and we…
Arousal from sleep secondary to respiratory stimuli has been historically conceptualized as a protective mechanism that results in apnea termination and resumption of breathing—a sequence…
